Coherus Biosciences's total assets for Q2 2025 were $439.46M, an increase of 18.43% from the previous quarter. CHRS total liabilities were $319.64M for the fiscal quarter, a -42.36% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.